| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Postoperative Complications | 36 | 2024 | 2314 | 5.760 |
Why?
|
| Hospitals | 22 | 2024 | 303 | 4.830 |
Why?
|
| Venous Thromboembolism | 13 | 2024 | 161 | 4.730 |
Why?
|
| Colorectal Neoplasms | 16 | 2024 | 980 | 4.430 |
Why?
|
| Liver Neoplasms | 16 | 2024 | 755 | 4.310 |
Why?
|
| Hepatic Artery | 9 | 2024 | 84 | 3.710 |
Why?
|
| Colonic Neoplasms | 10 | 2024 | 572 | 3.700 |
Why?
|
| Pancreatic Neoplasms | 17 | 2025 | 684 | 3.590 |
Why?
|
| Surgical Procedures, Operative | 13 | 2024 | 206 | 3.540 |
Why?
|
| Adenocarcinoma | 19 | 2023 | 1185 | 3.400 |
Why?
|
| Infusions, Intra-Arterial | 9 | 2024 | 36 | 3.200 |
Why?
|
| Patient Discharge | 13 | 2024 | 326 | 3.110 |
Why?
|
| Colectomy | 11 | 2022 | 175 | 2.890 |
Why?
|
| Neoplasms | 19 | 2023 | 3065 | 2.840 |
Why?
|
| Esophageal Neoplasms | 11 | 2024 | 332 | 2.530 |
Why?
|
| Quality Indicators, Health Care | 7 | 2021 | 149 | 2.480 |
Why?
|
| Digestive System Surgical Procedures | 7 | 2024 | 128 | 2.430 |
Why?
|
| Aftercare | 7 | 2023 | 88 | 2.410 |
Why?
|
| Appendiceal Neoplasms | 3 | 2021 | 31 | 2.130 |
Why?
|
| Quality Improvement | 18 | 2024 | 457 | 2.110 |
Why?
|
| Humans | 155 | 2025 | 89961 | 2.060 |
Why?
|
| United States | 48 | 2025 | 7108 | 2.000 |
Why?
|
| Esophagectomy | 8 | 2021 | 91 | 1.940 |
Why?
|
| Retrospective Studies | 49 | 2024 | 9210 | 1.930 |
Why?
|
| Gastrointestinal Neoplasms | 4 | 2024 | 112 | 1.910 |
Why?
|
| Pancreatectomy | 8 | 2025 | 164 | 1.880 |
Why?
|
| Patient Readmission | 13 | 2024 | 355 | 1.820 |
Why?
|
| Aged | 68 | 2025 | 19254 | 1.720 |
Why?
|
| Neoplasm Staging | 23 | 2024 | 2000 | 1.660 |
Why?
|
| Lymph Node Excision | 6 | 2023 | 220 | 1.540 |
Why?
|
| Lymph Nodes | 9 | 2023 | 550 | 1.520 |
Why?
|
| Quality of Health Care | 10 | 2024 | 387 | 1.520 |
Why?
|
| Hepatectomy | 8 | 2024 | 172 | 1.510 |
Why?
|
| Adenocarcinoma, Mucinous | 2 | 2021 | 48 | 1.500 |
Why?
|
| Surgical Oncology | 2 | 2022 | 28 | 1.490 |
Why?
|
| Medicare | 9 | 2023 | 427 | 1.480 |
Why?
|
| Healthcare Disparities | 6 | 2024 | 432 | 1.480 |
Why?
|
| General Surgery | 6 | 2021 | 236 | 1.460 |
Why?
|
| Middle Aged | 68 | 2025 | 26146 | 1.450 |
Why?
|
| Stomach Neoplasms | 6 | 2023 | 288 | 1.420 |
Why?
|
| Surgeons | 5 | 2021 | 249 | 1.420 |
Why?
|
| Male | 79 | 2025 | 42674 | 1.390 |
Why?
|
| Colorectal Surgery | 3 | 2016 | 22 | 1.360 |
Why?
|
| Female | 81 | 2025 | 46587 | 1.350 |
Why?
|
| Guidelines as Topic | 2 | 2021 | 158 | 1.340 |
Why?
|
| Postoperative Care | 4 | 2016 | 231 | 1.340 |
Why?
|
| Risk Adjustment | 9 | 2016 | 38 | 1.330 |
Why?
|
| Length of Stay | 9 | 2024 | 749 | 1.250 |
Why?
|
| Chemotherapy, Adjuvant | 9 | 2023 | 476 | 1.220 |
Why?
|
| Rectal Neoplasms | 4 | 2020 | 129 | 1.150 |
Why?
|
| Quality Assurance, Health Care | 5 | 2022 | 225 | 1.130 |
Why?
|
| Risk Assessment | 14 | 2024 | 2327 | 1.070 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2021 | 1352 | 1.010 |
Why?
|
| Cholangiocarcinoma | 3 | 2023 | 81 | 1.010 |
Why?
|
| Chemoprevention | 3 | 2023 | 92 | 1.010 |
Why?
|
| Neoadjuvant Therapy | 8 | 2022 | 376 | 1.010 |
Why?
|
| Surgical Wound Infection | 6 | 2022 | 202 | 1.000 |
Why?
|
| Bile Duct Neoplasms | 3 | 2023 | 95 | 1.000 |
Why?
|
| Registries | 7 | 2020 | 808 | 0.980 |
Why?
|
| Risk Factors | 21 | 2025 | 5558 | 0.980 |
Why?
|
| Nomograms | 1 | 2025 | 32 | 0.960 |
Why?
|
| Quality Control | 2 | 2022 | 117 | 0.950 |
Why?
|
| Treatment Outcome | 22 | 2024 | 8273 | 0.930 |
Why?
|
| Medical Oncology | 4 | 2023 | 384 | 0.920 |
Why?
|
| Infusion Pumps, Implantable | 3 | 2023 | 25 | 0.920 |
Why?
|
| Biliary Tract Neoplasms | 2 | 2024 | 34 | 0.890 |
Why?
|
| Liver Failure | 2 | 2024 | 68 | 0.890 |
Why?
|
| Patient Compliance | 2 | 2016 | 230 | 0.880 |
Why?
|
| Feasibility Studies | 4 | 2023 | 785 | 0.880 |
Why?
|
| Laparoscopy | 7 | 2020 | 780 | 0.880 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2021 | 841 | 0.870 |
Why?
|
| Delivery of Health Care | 2 | 2021 | 437 | 0.860 |
Why?
|
| Follow-Up Studies | 20 | 2024 | 3678 | 0.840 |
Why?
|
| Hospitals, High-Volume | 4 | 2024 | 38 | 0.830 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2022 | 17 | 0.820 |
Why?
|
| Medicaid | 3 | 2023 | 242 | 0.810 |
Why?
|
| Health Status Disparities | 2 | 2023 | 191 | 0.800 |
Why?
|
| Practice Guidelines as Topic | 4 | 2018 | 1055 | 0.790 |
Why?
|
| Drainage | 2 | 2020 | 165 | 0.780 |
Why?
|
| Nursing Staff, Hospital | 1 | 2022 | 42 | 0.770 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2022 | 77 | 0.770 |
Why?
|
| Personnel Staffing and Scheduling | 2 | 2022 | 96 | 0.760 |
Why?
|
| Minimally Invasive Surgical Procedures | 3 | 2020 | 258 | 0.760 |
Why?
|
| Research Report | 1 | 2021 | 44 | 0.750 |
Why?
|
| Health Literacy | 1 | 2022 | 73 | 0.740 |
Why?
|
| Inflammatory Bowel Diseases | 2 | 2020 | 594 | 0.740 |
Why?
|
| Models, Statistical | 4 | 2014 | 576 | 0.730 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 8 | 2024 | 2506 | 0.710 |
Why?
|
| Prospective Payment System | 1 | 2020 | 7 | 0.700 |
Why?
|
| Preoperative Care | 4 | 2019 | 395 | 0.700 |
Why?
|
| Survival Rate | 12 | 2025 | 1899 | 0.700 |
Why?
|
| Databases, Factual | 12 | 2024 | 866 | 0.690 |
Why?
|
| Occupational Exposure | 1 | 2021 | 87 | 0.690 |
Why?
|
| Logistic Models | 13 | 2020 | 1214 | 0.690 |
Why?
|
| Organizational Objectives | 1 | 2020 | 24 | 0.690 |
Why?
|
| Observational Studies as Topic | 1 | 2020 | 50 | 0.680 |
Why?
|
| Efficiency | 1 | 2020 | 40 | 0.680 |
Why?
|
| Comparative Effectiveness Research | 1 | 2020 | 53 | 0.670 |
Why?
|
| Continuity of Patient Care | 1 | 2021 | 172 | 0.660 |
Why?
|
| Professional Competence | 1 | 2020 | 69 | 0.660 |
Why?
|
| Product Recalls and Withdrawals | 1 | 2019 | 2 | 0.660 |
Why?
|
| Cholestasis | 1 | 2019 | 45 | 0.650 |
Why?
|
| Adult | 35 | 2024 | 26816 | 0.650 |
Why?
|
| Statistics as Topic | 1 | 2020 | 234 | 0.650 |
Why?
|
| Anesthesia | 1 | 2021 | 169 | 0.640 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2019 | 79 | 0.630 |
Why?
|
| Hyperthermia, Induced | 1 | 2019 | 73 | 0.620 |
Why?
|
| Skin Neoplasms | 2 | 2022 | 598 | 0.610 |
Why?
|
| Lung Neoplasms | 5 | 2024 | 2370 | 0.590 |
Why?
|
| National Cancer Institute (U.S.) | 2 | 2014 | 72 | 0.560 |
Why?
|
| Abdominal Neoplasms | 2 | 2020 | 39 | 0.560 |
Why?
|
| Endosonography | 1 | 2017 | 99 | 0.550 |
Why?
|
| Reoperation | 6 | 2024 | 604 | 0.540 |
Why?
|
| Multivariate Analysis | 12 | 2019 | 983 | 0.530 |
Why?
|
| Aged, 80 and over | 22 | 2024 | 6783 | 0.520 |
Why?
|
| Prognosis | 16 | 2024 | 3798 | 0.510 |
Why?
|
| Socioeconomic Factors | 3 | 2024 | 596 | 0.510 |
Why?
|
| Elective Surgical Procedures | 3 | 2021 | 129 | 0.510 |
Why?
|
| Guideline Adherence | 5 | 2023 | 234 | 0.500 |
Why?
|
| Biomedical Research | 1 | 2020 | 405 | 0.500 |
Why?
|
| Chemoradiotherapy | 3 | 2013 | 306 | 0.490 |
Why?
|
| Obesity, Morbid | 3 | 2020 | 241 | 0.470 |
Why?
|
| Combined Modality Therapy | 8 | 2021 | 1704 | 0.470 |
Why?
|
| Precision Medicine | 1 | 2019 | 413 | 0.470 |
Why?
|
| Evidence-Based Medicine | 2 | 2020 | 435 | 0.450 |
Why?
|
| Esophagoscopy | 1 | 2014 | 90 | 0.450 |
Why?
|
| Lymphatic Metastasis | 7 | 2023 | 495 | 0.450 |
Why?
|
| Robotic Surgical Procedures | 1 | 2019 | 319 | 0.450 |
Why?
|
| Hospital Costs | 1 | 2014 | 109 | 0.440 |
Why?
|
| Hospitalization | 2 | 2023 | 888 | 0.440 |
Why?
|
| Hospital Mortality | 3 | 2013 | 408 | 0.430 |
Why?
|
| Research Design | 4 | 2021 | 591 | 0.430 |
Why?
|
| Cancer Care Facilities | 1 | 2013 | 30 | 0.430 |
Why?
|
| Biomarkers, Tumor | 2 | 2021 | 1545 | 0.420 |
Why?
|
| Frailty | 2 | 2024 | 79 | 0.420 |
Why?
|
| Efficiency, Organizational | 1 | 2013 | 59 | 0.420 |
Why?
|
| Gastrectomy | 4 | 2020 | 71 | 0.410 |
Why?
|
| Ovarian Neoplasms | 1 | 2019 | 772 | 0.410 |
Why?
|
| Tertiary Care Centers | 1 | 2013 | 110 | 0.400 |
Why?
|
| Antineoplastic Agents | 3 | 2019 | 2331 | 0.400 |
Why?
|
| Veterans | 1 | 2013 | 85 | 0.400 |
Why?
|
| Cohort Studies | 10 | 2022 | 2886 | 0.380 |
Why?
|
| Appendectomy | 2 | 2022 | 39 | 0.380 |
Why?
|
| Odds Ratio | 6 | 2020 | 682 | 0.380 |
Why?
|
| Colonoscopy | 4 | 2021 | 281 | 0.380 |
Why?
|
| Thoracic Neoplasms | 1 | 2011 | 66 | 0.380 |
Why?
|
| Time-to-Treatment | 1 | 2013 | 124 | 0.380 |
Why?
|
| Sigmoid Neoplasms | 1 | 2011 | 9 | 0.370 |
Why?
|
| Diverticulum, Colon | 1 | 2011 | 10 | 0.370 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2024 | 1131 | 0.360 |
Why?
|
| Breast Neoplasms | 4 | 2019 | 3022 | 0.350 |
Why?
|
| Morbidity | 2 | 2022 | 149 | 0.340 |
Why?
|
| Organizational Culture | 2 | 2020 | 35 | 0.340 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2024 | 399 | 0.330 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2023 | 608 | 0.320 |
Why?
|
| Quality of Life | 1 | 2017 | 1682 | 0.320 |
Why?
|
| Neoplasm Invasiveness | 1 | 2011 | 569 | 0.320 |
Why?
|
| Sentinel Lymph Node | 2 | 2018 | 17 | 0.320 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2016 | 1098 | 0.310 |
Why?
|
| Pancreaticoduodenectomy | 2 | 2019 | 83 | 0.310 |
Why?
|
| Telemedicine | 2 | 2021 | 195 | 0.300 |
Why?
|
| Pneumonectomy | 4 | 2024 | 211 | 0.290 |
Why?
|
| Sentinel Lymph Node Biopsy | 4 | 2018 | 73 | 0.280 |
Why?
|
| Hospitals, Low-Volume | 2 | 2024 | 19 | 0.280 |
Why?
|
| Body Mass Index | 2 | 2011 | 776 | 0.260 |
Why?
|
| Confidence Intervals | 4 | 2014 | 221 | 0.260 |
Why?
|
| Patient Safety | 2 | 2018 | 219 | 0.260 |
Why?
|
| Focus Groups | 3 | 2021 | 177 | 0.260 |
Why?
|
| Postoperative Period | 2 | 2020 | 301 | 0.250 |
Why?
|
| Bile Ducts, Intrahepatic | 2 | 2022 | 72 | 0.250 |
Why?
|
| Benchmarking | 3 | 2023 | 79 | 0.250 |
Why?
|
| Outpatients | 2 | 2023 | 101 | 0.250 |
Why?
|
| Gastric Bypass | 2 | 2020 | 113 | 0.250 |
Why?
|
| Severity of Illness Index | 2 | 2014 | 1862 | 0.250 |
Why?
|
| Fluorouracil | 2 | 2023 | 549 | 0.250 |
Why?
|
| Time Factors | 6 | 2020 | 5358 | 0.250 |
Why?
|
| Melanoma | 3 | 2018 | 471 | 0.240 |
Why?
|
| Illinois | 3 | 2023 | 485 | 0.240 |
Why?
|
| Patient Selection | 3 | 2019 | 682 | 0.230 |
Why?
|
| Predictive Value of Tests | 4 | 2014 | 1732 | 0.230 |
Why?
|
| Drug Therapy | 2 | 2022 | 69 | 0.230 |
Why?
|
| Bariatric Surgery | 2 | 2020 | 200 | 0.220 |
Why?
|
| Analysis of Variance | 4 | 2013 | 899 | 0.220 |
Why?
|
| Prospective Studies | 6 | 2023 | 4329 | 0.220 |
Why?
|
| Decision Support Techniques | 3 | 2014 | 168 | 0.220 |
Why?
|
| Neoplasm Grading | 3 | 2013 | 376 | 0.210 |
Why?
|
| Young Adult | 7 | 2019 | 6409 | 0.210 |
Why?
|
| Reproducibility of Results | 3 | 2020 | 2767 | 0.210 |
Why?
|
| Thyroidectomy | 1 | 2023 | 171 | 0.210 |
Why?
|
| Referral and Consultation | 2 | 2018 | 345 | 0.210 |
Why?
|
| Burnout, Professional | 2 | 2021 | 102 | 0.200 |
Why?
|
| Drug Resistance, Microbial | 1 | 2022 | 75 | 0.200 |
Why?
|
| Pancreatic Fistula | 2 | 2019 | 17 | 0.200 |
Why?
|
| Esophagogastric Junction | 2 | 2012 | 34 | 0.200 |
Why?
|
| Surgery Department, Hospital | 2 | 2014 | 44 | 0.200 |
Why?
|
| Thoracotomy | 2 | 2012 | 64 | 0.200 |
Why?
|
| Machine Learning | 1 | 2024 | 270 | 0.200 |
Why?
|
| Emergency Service, Hospital | 2 | 2023 | 528 | 0.200 |
Why?
|
| Comprehension | 1 | 2022 | 81 | 0.200 |
Why?
|
| CA-125 Antigen | 1 | 2021 | 22 | 0.190 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2021 | 40 | 0.190 |
Why?
|
| Internship and Residency | 3 | 2021 | 1062 | 0.190 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2023 | 195 | 0.190 |
Why?
|
| Communication Barriers | 1 | 2021 | 30 | 0.190 |
Why?
|
| Education, Medical, Graduate | 3 | 2021 | 402 | 0.190 |
Why?
|
| Incidence | 2 | 2024 | 1603 | 0.190 |
Why?
|
| Office Visits | 1 | 2021 | 50 | 0.180 |
Why?
|
| Checklist | 1 | 2021 | 64 | 0.180 |
Why?
|
| Cross-Sectional Studies | 4 | 2021 | 1730 | 0.180 |
Why?
|
| Anticoagulants | 2 | 2022 | 432 | 0.180 |
Why?
|
| Propensity Score | 2 | 2019 | 149 | 0.180 |
Why?
|
| Publishing | 1 | 2021 | 90 | 0.180 |
Why?
|
| Medical Errors | 1 | 2021 | 115 | 0.180 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2020 | 22 | 0.170 |
Why?
|
| Margins of Excision | 1 | 2020 | 39 | 0.170 |
Why?
|
| Equipment Design | 1 | 2021 | 422 | 0.170 |
Why?
|
| Pelvic Neoplasms | 1 | 2020 | 44 | 0.170 |
Why?
|
| Survival Analysis | 6 | 2020 | 1497 | 0.170 |
Why?
|
| Patient Preference | 1 | 2020 | 111 | 0.170 |
Why?
|
| Health Policy | 2 | 2019 | 188 | 0.170 |
Why?
|
| Qualitative Research | 1 | 2021 | 306 | 0.170 |
Why?
|
| Embolization, Therapeutic | 1 | 2022 | 265 | 0.160 |
Why?
|
| Patient Education as Topic | 1 | 2022 | 365 | 0.160 |
Why?
|
| Gastroparesis | 1 | 2019 | 14 | 0.160 |
Why?
|
| Reference Standards | 1 | 2019 | 144 | 0.160 |
Why?
|
| Health Status Indicators | 1 | 2019 | 103 | 0.160 |
Why?
|
| Colon | 1 | 2022 | 521 | 0.160 |
Why?
|
| Physicians, Women | 1 | 2019 | 57 | 0.160 |
Why?
|
| Treatment Failure | 1 | 2019 | 278 | 0.160 |
Why?
|
| Fundoplication | 1 | 2019 | 79 | 0.160 |
Why?
|
| Academic Medical Centers | 2 | 2020 | 384 | 0.160 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2019 | 74 | 0.160 |
Why?
|
| SEER Program | 1 | 2019 | 205 | 0.160 |
Why?
|
| Health Personnel | 1 | 2020 | 214 | 0.150 |
Why?
|
| Needs Assessment | 1 | 2019 | 161 | 0.150 |
Why?
|
| Career Choice | 1 | 2019 | 148 | 0.150 |
Why?
|
| Algorithms | 2 | 2018 | 1913 | 0.150 |
Why?
|
| Communication | 1 | 2021 | 461 | 0.150 |
Why?
|
| Health Status | 1 | 2019 | 371 | 0.140 |
Why?
|
| Anti-Bacterial Agents | 1 | 2022 | 798 | 0.140 |
Why?
|
| Accreditation | 2 | 2014 | 61 | 0.140 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 1169 | 0.140 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2018 | 120 | 0.130 |
Why?
|
| Learning | 1 | 2019 | 286 | 0.130 |
Why?
|
| Physical Examination | 1 | 2017 | 149 | 0.130 |
Why?
|
| Stents | 1 | 2019 | 412 | 0.130 |
Why?
|
| Adolescent | 6 | 2019 | 9340 | 0.130 |
Why?
|
| Endoscopy | 1 | 2019 | 352 | 0.130 |
Why?
|
| Patient Satisfaction | 1 | 2018 | 460 | 0.120 |
Why?
|
| Neuroendocrine Tumors | 2 | 2007 | 124 | 0.120 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2013 | 144 | 0.120 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 654 | 0.120 |
Why?
|
| Health Care Surveys | 2 | 2018 | 281 | 0.110 |
Why?
|
| Curriculum | 1 | 2018 | 573 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2021 | 2677 | 0.110 |
Why?
|
| Tissue Expansion Devices | 1 | 2013 | 8 | 0.110 |
Why?
|
| Surveys and Questionnaires | 4 | 2023 | 2655 | 0.110 |
Why?
|
| Physician-Patient Relations | 1 | 2018 | 625 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2013 | 855 | 0.110 |
Why?
|
| Malpractice | 1 | 2013 | 57 | 0.110 |
Why?
|
| Cost-Benefit Analysis | 2 | 2013 | 467 | 0.110 |
Why?
|
| Decision Making | 1 | 2018 | 670 | 0.110 |
Why?
|
| Breast Implants | 1 | 2013 | 26 | 0.100 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 2018 | 0.100 |
Why?
|
| Clinical Competence | 1 | 2018 | 796 | 0.100 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2014 | 101 | 0.100 |
Why?
|
| Pancreatic Diseases | 1 | 2013 | 53 | 0.100 |
Why?
|
| Emergency Medical Services | 1 | 2016 | 244 | 0.100 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2014 | 114 | 0.100 |
Why?
|
| Pandemics | 3 | 2024 | 778 | 0.100 |
Why?
|
| American Cancer Society | 1 | 2012 | 13 | 0.100 |
Why?
|
| Prosthesis Failure | 1 | 2013 | 117 | 0.100 |
Why?
|
| Professional Practice | 1 | 2012 | 46 | 0.100 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2012 | 30 | 0.100 |
Why?
|
| Calibration | 1 | 2012 | 103 | 0.100 |
Why?
|
| Regression Analysis | 1 | 2013 | 591 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2021 | 3475 | 0.100 |
Why?
|
| Observation | 1 | 2011 | 38 | 0.100 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2011 | 23 | 0.090 |
Why?
|
| Interprofessional Relations | 1 | 2012 | 121 | 0.090 |
Why?
|
| Mammaplasty | 1 | 2013 | 110 | 0.090 |
Why?
|
| Gastroplasty | 1 | 2011 | 25 | 0.090 |
Why?
|
| Forecasting | 1 | 2012 | 304 | 0.090 |
Why?
|
| Pancreas | 1 | 2013 | 253 | 0.090 |
Why?
|
| Program Evaluation | 1 | 2012 | 312 | 0.090 |
Why?
|
| Physicians | 1 | 2018 | 692 | 0.090 |
Why?
|
| Sigmoidoscopy | 1 | 2011 | 36 | 0.090 |
Why?
|
| False Negative Reactions | 1 | 2011 | 63 | 0.090 |
Why?
|
| Geriatric Assessment | 1 | 2012 | 182 | 0.090 |
Why?
|
| Age Factors | 4 | 2020 | 1880 | 0.090 |
Why?
|
| Abdominal Pain | 1 | 2011 | 142 | 0.080 |
Why?
|
| Piperazines | 1 | 2011 | 283 | 0.080 |
Why?
|
| Job Satisfaction | 2 | 2019 | 79 | 0.080 |
Why?
|
| Bone Neoplasms | 1 | 2011 | 321 | 0.080 |
Why?
|
| Pyrimidines | 1 | 2011 | 371 | 0.080 |
Why?
|
| Hospitals, Veterans | 1 | 2007 | 21 | 0.070 |
Why?
|
| Hospitals, Community | 2 | 2023 | 32 | 0.070 |
Why?
|
| Principal Component Analysis | 2 | 2019 | 161 | 0.070 |
Why?
|
| Florida | 1 | 2023 | 60 | 0.060 |
Why?
|
| California | 1 | 2023 | 146 | 0.050 |
Why?
|
| Yttrium Radioisotopes | 1 | 2022 | 58 | 0.050 |
Why?
|
| Rural Population | 1 | 2022 | 147 | 0.050 |
Why?
|
| Obesity | 1 | 2008 | 972 | 0.050 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2013 | 290 | 0.050 |
Why?
|
| Patient Outcome Assessment | 1 | 2021 | 84 | 0.040 |
Why?
|
| Self Report | 1 | 2021 | 297 | 0.040 |
Why?
|
| Sexual Harassment | 1 | 2019 | 9 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 1 | 2019 | 270 | 0.040 |
Why?
|
| Intraabdominal Infections | 1 | 2019 | 10 | 0.040 |
Why?
|
| Gastric Emptying | 1 | 2019 | 25 | 0.040 |
Why?
|
| Ablation Techniques | 1 | 2019 | 38 | 0.040 |
Why?
|
| Hospital Bed Capacity | 1 | 2018 | 20 | 0.040 |
Why?
|
| Health Surveys | 1 | 2019 | 240 | 0.040 |
Why?
|
| ROC Curve | 2 | 2013 | 778 | 0.040 |
Why?
|
| Hysterectomy | 1 | 2020 | 156 | 0.040 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2019 | 35 | 0.040 |
Why?
|
| Insurance Claim Review | 1 | 2018 | 45 | 0.040 |
Why?
|
| Reimbursement, Incentive | 1 | 2018 | 37 | 0.040 |
Why?
|
| Ownership | 1 | 2018 | 26 | 0.040 |
Why?
|
| Axilla | 1 | 2018 | 103 | 0.040 |
Why?
|
| Operative Time | 1 | 2018 | 147 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2019 | 1048 | 0.040 |
Why?
|
| Smoking | 1 | 2021 | 625 | 0.040 |
Why?
|
| Data Interpretation, Statistical | 1 | 2018 | 303 | 0.030 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2020 | 296 | 0.030 |
Why?
|
| Consensus | 1 | 2018 | 366 | 0.030 |
Why?
|
| Carcinoma | 1 | 2020 | 438 | 0.030 |
Why?
|
| Prostatectomy | 1 | 2020 | 473 | 0.030 |
Why?
|
| Observer Variation | 1 | 2018 | 614 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 281 | 0.030 |
Why?
|
| Renal Insufficiency | 1 | 2016 | 97 | 0.030 |
Why?
|
| Relative Value Scales | 1 | 2014 | 9 | 0.030 |
Why?
|
| Lawyers | 1 | 2013 | 2 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2014 | 94 | 0.030 |
Why?
|
| Ulcer | 1 | 2013 | 37 | 0.030 |
Why?
|
| Breast Implantation | 1 | 2013 | 14 | 0.030 |
Why?
|
| Mitosis | 1 | 2013 | 152 | 0.030 |
Why?
|
| Medicine | 1 | 2013 | 91 | 0.030 |
Why?
|
| Medical Records | 1 | 2013 | 120 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 358 | 0.030 |
Why?
|
| Insurance, Health | 1 | 2013 | 164 | 0.020 |
Why?
|
| Imatinib Mesylate | 1 | 2011 | 126 | 0.020 |
Why?
|
| Mastectomy | 1 | 2013 | 246 | 0.020 |
Why?
|
| Child | 1 | 2022 | 7240 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2013 | 848 | 0.020 |
Why?
|
| Benzamides | 1 | 2011 | 234 | 0.020 |
Why?
|
| Sepsis | 1 | 2014 | 329 | 0.020 |
Why?
|
| Weight Loss | 1 | 2011 | 233 | 0.020 |
Why?
|
| Comorbidity | 1 | 2013 | 953 | 0.020 |
Why?
|
| Disease Management | 1 | 2011 | 327 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2013 | 1066 | 0.020 |
Why?
|
| Prostatic Neoplasms | 1 | 2020 | 1744 | 0.020 |
Why?
|
| Laparotomy | 1 | 2008 | 68 | 0.020 |
Why?
|
| Adenoma, Islet Cell | 1 | 2007 | 28 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2008 | 305 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2007 | 94 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2011 | 584 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2007 | 1533 | 0.010 |
Why?
|